Q4 2024 Earnings Call Mar 10, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. P ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report) and ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

KEY TAKEAWAYS U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset ...

BioNTech (BNTX) reported a decline in fourth-quarter revenue and projected full-year sales to fall again in 2025, while the German drugmaker announced plans to ramp up research and development efforts ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

For 2025, BioNTech management anticipates revenue between 1.7 billion euros and 2.2 billion euros, with planned R&D outlays reaching between 2.6 billion euros and 2.8 billion euros. The company's ...

BoC Interest Rate Decision (Mar.) The Bank of Canada reduced its target for the overnight rate in February to 3%, with the ...

SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...